Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
News and updates for Enanta Pharmaceuticals, Inc. (ENTA) focus on its progress as a clinical-stage biotechnology company developing small molecule drugs for viral infections and immunological diseases. Company press releases frequently highlight clinical data, regulatory designations, pipeline milestones, financial results, capital raises, and intellectual property developments.
Investors following ENTA news can expect detailed coverage of RSV clinical programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an oral L-protein inhibitor. Enanta regularly reports Phase 2 and Phase 2b trial readouts in high-risk adult and pediatric RSV populations, human viral challenge data, and analyses of symptom resolution, viral load reductions, and safety outcomes. Updates also cover Phase 3-enabling activities and interactions with the U.S. Food and Drug Administration on trial design and registration pathways.
News items also track Enanta’s immunology pipeline, such as the nomination of EPS-3903, an oral STAT6 inhibitor for atopic dermatitis and other type 2 immune-driven diseases, and the selection of EDP-978, an oral KIT inhibitor for chronic spontaneous urticaria and other mast cell–driven conditions. Announcements describe preclinical potency, selectivity, and planned IND filings and early clinical timelines, as well as the expansion of discovery programs targeting MRGPRX2.
On the corporate side, ENTA news includes quarterly and annual financial results, commentary on royalty revenue from AbbVie’s HCV regimen MAVYRET/MAVIRET, and disclosures about cash runway expectations. Coverage also includes public equity offerings, underwritten offering terms, and use of proceeds, along with patent litigation developments, such as Enanta’s infringement action in the Unified Patent Court related to its coronavirus protease inhibitor patent. For ongoing insight into ENTA’s clinical, financial, and legal developments, this news feed aggregates the company’s latest official announcements.
Enanta Pharmaceuticals (NASDAQ: ENTA), a clinical-stage biotechnology firm specializing in small molecule drugs for virology and immunology, has announced its participation at the Jefferies Global Healthcare Conference. The event will feature a fireside chat with President and CEO Jay R. Luly, Ph.D., and Chief Product Strategy Officer Tara L. Kieffer, Ph.D. The session is set for June 5, 2024, at 7:30 a.m. ET in New York, NY. A live webcast of the discussion will be available on Enanta's website, with a replay accessible for at least 30 days post-event.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will participate in the JMP Securities Life Sciences Conference with their CEO and Chief Product Strategy Officer, discussing small molecule drugs for virology and immunology. The event will be live webcasted and available for replay on Enanta's website.
Enanta Pharmaceuticals, a clinical-stage biotechnology company, reported financial results for Q2 of fiscal year 2024. The company anticipates reporting topline data from RSV studies, phase 2 study of Zelicapavir, and CSU development candidate selection in 2024. Enanta's revenue was $17.1 million, with research and development expenses of $35.6 million. The company's operations are supported by $300.3 million in cash and marketable securities. Enanta is focused on advancing antiviral treatments for RSV and immunology indications.
Enanta Pharmaceuticals, Inc. announced inducement grants to its new Chief Legal Officer, Matthew P. Kowalsky, involving stock options, performance share units, and relative total stockholder return units under the company's 2024 Inducement Stock Incentive Plan. These awards are aimed at incentivizing Mr. Kowalsky's performance and retention within the company.
Enanta Pharmaceuticals, Inc. announced the appointment of Matthew P. Kowalsky as Chief Legal Officer. With over 20 years of legal experience in the life sciences industry, he will lead all legal and compliance activities for Enanta, providing strategic guidance and corporate governance oversight. Kowalsky's background includes roles at Sigilon Therapeutics, Proteon Therapeutics, Sanofi Genzyme, Cubist Pharmaceuticals, ARIAD Pharmaceuticals, and Lantheus Medical Imaging, among others. His expertise in corporate governance, public company reporting, intellectual property, financing, and business development makes him a valuable addition to Enanta's leadership team.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.